Related Experiment Video

Updated: Aug 9, 2026

Suppression of Pro-fibrotic Signaling Potentiates Factor-mediated Reprogramming of Mouse Embryonic Fibroblasts into Induced Cardiomyocytes
09:16

Suppression of Pro-fibrotic Signaling Potentiates Factor-mediated Reprogramming of Mouse Embryonic Fibroblasts into Induced Cardiomyocytes

Published on: June 3, 2018

Cellular events linked to cardiac remodeling in heart failure: targets for pharmacologic intervention

M R Piano1, S D Kim, C Jarvis

  • 1College of Nursing, University of Illinois at Chicago, USA.

The Journal of Cardiovascular Nursing
|July 21, 2000
PubMed

Insights

Heart failure involves complex changes in heart muscle cells and structure, not just blood flow issues. Understanding these cellular changes, like myocyte remodeling and apoptosis, is key to developing new treatments.

Area of Science:

  • Cardiology
  • Cellular Biology
  • Pathophysiology

Background:

  • Heart failure understanding has shifted from a hemodynamic disorder to a complex syndrome.
  • Previously, heart failure was viewed primarily as a hemodynamic issue involving renal and hormonal dysfunction.
  • The current paradigm recognizes abnormal cellular processes as central to heart failure progression.

Purpose of the Study:

  • To explore the role of myocyte and nonmyocyte structural changes in heart failure progression.
  • To elucidate the complex pathophysiology of heart failure beyond hemodynamic factors.
  • To provide insights for developing novel pharmacologic therapies for heart failure.

Main Methods:

  • Review of current literature on heart failure pathophysiology.
  • Analysis of cellular and structural remodeling mechanisms in the failing heart.
  • Discussion of the link between initiating events (e.g., myocardial infarction) and disease progression.

Main Results:

  • Heart failure is characterized by abnormal myocyte growth, extracellular matrix proliferation, and apoptosis.
  • These cellular changes lead to significant structural remodeling of the heart and loss of ventricular function.
  • Myocardial infarction triggers a cascade of cellular and neurohormonal events contributing to ventricular remodeling.

Conclusions:

  • Structural remodeling and cellular changes are critical drivers of heart failure progression.
  • Understanding these cellular mechanisms is essential for advancing heart failure treatment strategies.
  • Newer pharmacologic approaches may target these specific cellular and structural alterations.

More Related Videos

Studying Left Ventricular Reverse Remodeling by Aortic Debanding in Rodents07:26

Studying Left Ventricular Reverse Remodeling by Aortic Debanding in Rodents

Published on: July 14, 2021

A Rat Model of Pressure Overload Induced Moderate Remodeling and Systolic Dysfunction as Opposed to Overt Systolic Heart Failure07:13

A Rat Model of Pressure Overload Induced Moderate Remodeling and Systolic Dysfunction as Opposed to Overt Systolic Heart Failure

Published on: April 30, 2020

Related Concept Videos

Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Cellular Adaptation II: Hypertrophy01:26

Cellular Adaptation II: Hypertrophy

Hypertrophy is the increase in the size of individual cells, resulting in the enlargement of a tissue or organ. Unlike hyperplasia, which involves an increase in cell number, hypertrophy is characterized by an increase in cell volume. This process often occurs in response to higher functional demand or hormonal stimulation, leading to the production of more structural proteins and organelles, thereby enhancing the cells' work capacity.There are two primary types of hypertrophy: physiological...